Join Oculis for an in-person and virtual R&D Day to provide an update on Oculis’ portfolio of innovative late-stage clinical candidates, highlight recent clinical data and next steps, as well as discuss future development programs and business strategy. It will feature world-renowned key opinion leaders:

Retina:

• David S. Boyer, MD (Keck School of Medicine, University of Southern California, and Retina Vitreous Associates Medical Group);
• Arshad M. Khanani, MD, MA, FASRS (Reno School of Medicine, University of Nevada, and Sierra Eye Associates);
• Baruch D. Kuppermann, MD, PhD (Department of Ophthalmology, University of California, Irvine and Gavin Herbert Eye Institute);
• Sebastian Wolf, MD, PhD (Department of Ophthalmology, University of Bern);

Inflammation and precision medicine:

• Anat Galor, MD, MSPH (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami);

Neuro-ophthalmology:

• Mark Kupersmith, MD (Icahn School of Medicine at Mount Sinai and New York Eye and Ear Infirmary);
• Leonard Levin, MD, PhD (Departments of Ophthalmology & Visual Sciences and Neurology & Neurosurgery, McGill University);
• Pablo Villoslada, MD, PhD (Department of Neurology, Hospital del Mar, Pompeu Fabra University);

The presentations will include an update on progress with both Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME), Licaminlimab (OCS-02)’s development plan with precision medicine in dry eye disease (DED) and an expanded data analysis from the ACUITY Phase 2 trial as well as the development plans for Privosegtor (OCS-05) in acute optic neuritis and beyond.

The event will also outline Oculis’ portfolio strategy to drive pipeline value and maximize resource deployment.

A live question and answer session will follow the formal presentations.